What are the funding trends in healthcare AI agents?

All funding deals in the healthcare AI agents market over the last years

Below is the table listing all the deals. You can find our methodology at the end of this page.

If you want a deeper understanding of the market and its current dynamics, get our healthcare AI agents market report.

Is healthcare AI agent funding slowing down this year?

Healthcare AI agent startups have raised less money and closed fewer deals this year than at the same point in 2025.

We tracked 88 equity deals worth at least $2.2B this year to date, compared with 102 deals worth at least $2.8B over the equivalent dates of 2025. That is a decline of 14% in deal count and 21% in disclosed capital. Part of the reason is that the sector had become known for exceptionally large rounds in clinical documentation and patient-facing automation.

Abridge's $300M Series D+ in June 2025 and Ambience Healthcare's $243M Series C in July 2025 illustrate the earlier funding environment. This year, the largest single financing in the market was Forus's $150M Series C in September 2026, four months after its own $125M Series B, alongside Assort Health's $120M Series C in June 2026 and Candid Health's $120M Series D+ in July 2026. Large deals are still closing, just fewer of them than during the peak.

Has healthcare AI agent funding lost all its earlier gains?

Healthcare AI agent funding has pulled back from its peak but remains well above the earlier baseline.

For the same January-to-November comparison window, funding increased from $1.3B in 2024 to at least $2.2B this year, up 70%. The number of deals moved from 63 to 88, an increase of 40%. It's not just one big round: both the money and the number of deals are up.

The underlying products have also changed. Abridge's $150M Series C in February 2024 was already funding clinical documentation at scale. More recent rounds include Latent Health's $80M Series A in March 2026 for medication-access workflows, Prosper AI's $30M Series A in June 2026 for patient access and billing, and Suki's $90M Series D+ in October 2026 for broader clinician tools. More companies now target medication access, billing and claims review, even as funding cools.

Have healthcare AI agents already beaten their funding record?

Healthcare AI agent startups have not yet matched the sector’s full-year funding record.

The year-to-date total is at least $2.2B, representing 72% of the at-least-$3.0B raised during the complete 2025 calendar year. Deal count is 76% of the 116 transactions recorded during that full year. This year is still incomplete. We neither annualize the total nor assume the remaining weeks will repeat the earlier pace.

The comparison also works the other way. This year's funding is already above the complete 2024 total of at least $1.4B, with the year-to-date total reaching 157% of that year's funding. Yet it remains short of 2025's stronger base. The big rounds keep coming: September 2026 alone included Forus, Heidi Health and Tandem Health closing major rounds. The sector has moved well beyond 2024, but it has yet to repeat the 2025 peak.

Was healthcare AI agent funding unusually strong before the slowdown?

Healthcare AI agent funding jumped dramatically in 2025, making it a difficult year to beat.

For all of 2025, the sector recorded 116 deals and at least $3.0B, compared with 77 deals and at least $1.4B for full-year 2024. The disclosed capital total increased 117%, and deal count rose 51%. Several companies contributed: Abridge, Ambience Healthcare, Hippocratic AI and Tennr were among the companies raising major rounds during 2025.

The timing matters. Abridge announced a $250M Series D+ in February 2025 and then a $300M Series D+ in June 2025, while Ambience Healthcare announced a $243M Series C in July 2025. Hippocratic AI raised a $141M Series B in January 2025 and a $126M Series C in November 2025. By contrast, 2024 had fewer giant rounds and a smaller base of funded businesses. Falling back from that peak does not mean buyers stopped wanting healthcare agents.

Are giant healthcare AI agent deals skewing this year’s numbers?

Giant healthcare AI agent rounds account for much of this year’s funding decline. Smaller deals have held up better.

Funding excluding rounds above $50M was at least $1.1B this year to date, 7% more than in the equivalent period of 2025. Excluding rounds above $100M produced at least $1.7B against at least $1.6B, up 4%. So the picture flips: total money is down, but the rounds below the giant ones are bringing in more.

Yet the count of financings still decreased, and the number of distinct funded companies fell from 90 to 84. That is good news for mid-sized checks, but fewer companies raised money overall. Candid Health's $120M Series D+ in July 2026, Forus's $150M Series C in September 2026 and Suki's $90M Series D+ in October 2026 show that investors still pay up for products that already work. They coexist with a narrower pipeline of financings, especially at the earliest stage.

Are investors paying more per healthcare AI agent round?

The typical healthcare AI agent funding check has grown even while total dollars raised have fallen.

The median disclosed round reached $16.0M this year to date, up 60% from $10.0M over the same period of 2025. The comparable period of 2024 had the same $10.0M median. The shift cannot be explained only by the largest deals: the $5M-to-under-$20M size bracket accounted for 36 deals this year, and the $20M-to-under-$50M bracket had 21 deals, compared with 40 and 19 deals respectively by this point last year.

Investors are still writing serious checks, but to fewer companies. Charta Health's $55M Series B in November 2026, Arintra's $25M Series B in August 2026 and Vitalize's $31M Series A in October 2026 show several different uses for these rounds: claims review, medical coding and staffing. The deals show what investors were willing to write, not what those companies earn.

Is the healthcare AI agent funding slump getting worse every quarter?

Not in dollars: quarterly healthcare AI agent funding rose from Q1 to Q3 2026, even though the deal count slipped a little each quarter.

The sector recorded $459M in Q1 2026, at least $630M in Q2 2026 and $775M in Q3 2026. Deal counts moved from 26 to 25 to 23 across those quarters. Thus the rise in disclosed capital through Q3 was not matched by an increase in the number of deals each quarter. Big closings lifted the quarterly totals even as the deal count slipped.

The earlier history makes this unevenness easier to see. Q1 2025 produced at least $826M and Q2 2025 produced $938M. Both were heavily influenced by large rounds, including Abridge's financings. A quarterly jump does not by itself establish that more founders can raise capital. More dollars in a quarter did not mean more rounds.

The table below shows quarterly activity, including the partial quarter and year-only dates.

Period	Deals	Capital
Q1 2024	18	$519M
Q2 2024	24	$327M
Q3 2024	11	$212M
Q4 2024	20	$333M
2024, quarter not known	4	$11M+
Q1 2025	24	$826M+
Q2 2025	32	$938M
Q3 2025	24	$580M
Q4 2025	34	$690M
2025, quarter not known	2	$11M
Q1 2026	26	$459M
Q2 2026	25	$630M+
Q3 2026	23	$775M
Q4 2026 (partial)	13	$337M
2026, quarter not known	1	Undisclosed

Quarters add up to fewer deals than the yearly totals: 4 deals of 2024, 2 of 2025 and 1 of 2026 are dated only by the year, so they count in the yearly totals but in no quarter.

Did healthcare AI agent funding finally rebound in Q3?

Healthcare AI agent funding bounced back in Q3, but investors did not fund more companies.

That quarter had 23 deals totaling $775M, against 25 deals and at least $630M in Q2 2026. September 2026 was particularly important: it included Forus's $150M Series C, Heidi Health's $100M Series C and Tandem Health's $100M Series B. Each was large enough to change how a quarterly total looked. The quarter therefore tells us that investors still have interest in major healthcare automation businesses, not that the entire funding pipeline accelerated.

The applications also matter. Forus is focused on medication access, Heidi develops documentation and supervised actions, and Tandem says it is expanding toward a clinic operating system. The companies serve related but different workflows, so the quarter was not merely a repeat of the U.S. documentation rounds that dominated parts of 2025. One good quarter in dollars is too little to call a fresh boom.

Does the current quarter show healthcare AI agents stalling?

The latest healthcare AI agent funding quarter is incomplete, so its smaller total proves very little.

So far, the quarter has 13 recorded deals and $337M. Comparing that partial tally with Q3 2026's completed 23 deals and $775M would mix unequal time periods. More useful evidence comes from completed deal announcements: Suki raised $90M in a Series D+ in October 2026, Vitalize raised $31M in a Series A in October 2026, and Charta Health raised $55M in a Series B in November 2026.

We should also avoid pretending that the latest months necessarily capture every financing immediately. Release timing, dates known only to the year, and undisclosed amounts can distort a quick reading of the last few weeks. Deal activity is weaker than at the same point in 2025. The unfinished quarter adds no firm verdict.

Are more healthcare AI agent startups raising Series A?

More healthcare AI agent startups are getting Series A checks now than at the comparable point in previous years.

This year to date, we tracked 38 Series A deals worth $729M, compared with 30 deals worth $617M over the same dates of 2025 and 15 deals worth $328M by the same point of 2024. Series A's share of all deals rose to 43%, compared with 29% in the equivalent 2025 period and 24% in the equivalent 2024 period. This shift appears in completed Series A deals across all three periods.

Latent Health's $80M Series A in March 2026, Prosper AI's $30M Series A in June 2026 and Vitalize's $31M Series A in October 2026 support a practical interpretation: a group of startups is being funded to scale beyond initial product development. Yet the data does not track commercial milestones for every company and cannot tell us how many founders tried but failed to raise a Series A. The Series A shift is clear even if we cannot see rejected pitches.

Is seed funding disappearing for healthcare AI agents?

Healthcare AI agent seed deals have dropped sharply after a much busier period.

We recorded 26 Seed deals and at least $138M this year to date, compared with 51 Seed deals and at least $264M by the same dates of 2025. The earlier comparable period of 2024 produced 30 Seed deals and $152M. Seed's deal share was 48% in the equivalent 2024 period and 50% in 2025, then fell to 30% this year. That sequence suggests a sharp recent change rather than a constant gradual decline.

New products still raise seed money. Ferry Health's $9M Seed in September 2026 targets appointment navigation, while Uncovr's $7M Seed in June 2026 works on video documentation and coding. But they now enter a market where established companies such as Assort Health and Suki can bundle additional tasks into existing healthcare customers' workflows. Epic's September 2026 Agent Factory announcement adds competition from health systems building agents in their record software. We cannot blame those competitors for the seed decline. The drop in completed deals is clear.

Are healthcare AI agents getting more late-stage funding?

Healthcare AI agent funding is moving toward Series A and Series B, but advanced rounds are still uncommon.

Series B accounted for 13 deals worth $683M this year to date, compared with 4 deals and $332M over the comparable period of 2025. Series B's share of deal count increased from 4% to 15%. Series C, however, moved from 9 deals to 4, and Series D+ from 4 deals to 2. Among deals with a named stage, later-stage rounds rose from 18% to 24% of deals, though the biggest stages became rarer.

More companies are getting middle-stage money while giant late rounds are harder to find. Forus's $125M Series B in May 2026, Tandem Health's $100M Series B in September 2026 and Charta Health's $55M Series B in November 2026 show how substantial middle-stage rounds can be. Suki's $90M Series D+ in October 2026 shows that mature funding is still available, but it is less frequent than in the peak comparison period. That changes what founders can expect after their first institutional round.

Is the funding boom for AI medical scribes over?

AI medical scribe startups are getting much less healthcare-agent funding than at the previous peak.

The category recorded 9 deals and at least $356M this year to date, versus 25 deals and $1.2B over the same period of 2025. Its share of disclosed capital fell from 43% to 16%, and its share of deal count moved from 25% to 10%. By the same point in 2024, the category had 14 deals and $488M, so today's weakness is not only a comparison with a single unusually large quarter.

Abridge and Ambience Healthcare help explain the scale of the earlier spike. Abridge's $250M Series D+ in February 2025 and $300M Series D+ in June 2025 supported documentation linked to clinical and billing workflows. Ambience Healthcare's $243M Series C in July 2025 backed coding and documentation integrity. Today, Heidi Health's $100M Series C in September 2026 and Tandem Health's $100M Series B in September 2026 show international demand for expanded clinician assistance, but the category no longer determines the entire market's direction.

The table below shows deal counts by category, ordered by capital raised this year.

Category	This year deals	Same 2025 deals	This year capital
Revenue Cycle Agents	18	15	$468M+
Prior Authorization Agents	8	8	$446M
Provider Operations Agents	20	25	$423M+
Clinical Documentation Agents	9	25	$356M+
Patient Access & Scheduling Agents	14	10	$230M
Care Coordination Agents	10	12	$162M
Patient Communication & Navigation Agents	9	7	$116M

Is AI medical billing now attracting the most funding?

AI medical billing companies are now receiving more healthcare-agent funding than any other category.

The category recorded 18 deals and at least $468M this year to date, versus 15 deals and $220M in the comparable period of 2025. Its share of disclosed capital rose from 8% to 21%, while its deal share increased from 15% to 20%. Prior authorization agents come close behind on capital, at $446M from only 8 deals. Unlike a category growing only through one financing, revenue cycle gained both activity and disclosed money.

Candid Health's $120M Series D+ in July 2026 supported an autonomous system for the route from service to reimbursement. Charta Health's $55M Series B in November 2026 targeted medical-chart checks before claims submission. Arintra's $25M Series B in August 2026 targeted autonomous coding. The companies attack different points in an expensive process. We cannot say they will beat existing billing vendors. Investors are backing several different points in the claims process.

Are patient-access AI agents gaining ground on scribes?

Patient-access and scheduling AI agents are taking a larger share of healthcare-agent deals this year.

We counted 14 deals worth $230M this year to date in that category, against 10 deals and $145M at the equivalent point of 2025. The deal share climbed from 10% to 16%, and the same period of 2024 had only 4 deals and $20M. Across all three periods, patient-access deals and dollars are growing.

Assort Health's $120M Series C in June 2026 supports voice and scheduling agents that also handle referrals and other patient-access tasks. Prosper AI's $30M Series A in June 2026 describes an even wider patient journey, including verification and billing. Both are distinct from merely generating a transcription of a visit. For clinics, booking a real appointment can be worth much more than answering a call. We do not measure that value for every funded company, but we can see where investors are writing checks.

Are prior-authorization AI agents a lasting funding bet?

Prior-authorization AI agents now attract some of the largest checks, but their deal count has not taken off.

The category recorded 8 deals and $446M this year to date, compared with 8 deals and $181M over the same 2025 period and 6 deals and $169M at the equivalent point of 2024. Its share of deals moved only from 8% to 9% versus the immediately preceding comparable period, while the capital share increased from 7% to 20%. Large checks therefore matter more than the number of startups being financed.

Latent Health's $80M Series A in March 2026 and Forus's $125M Series B in May 2026 and $150M Series C in September 2026 are examples of capital flowing to connected medication-access workflows. The federal context is also concrete: CMS's 2024 final rule set administrative changes beginning in 2026 and prior-authorization API requirements generally beginning in 2027, with specified exclusions. That creates a clear technology agenda for payers and providers, although our figures do not establish that regulation caused any particular investment decision.

Are patient communication AI agents being left behind?

Patient communication AI agents are closing more rounds, but drawing much less money than before.

This year's category recorded 9 deals and $116M, compared with 7 deals and at least $349M over the equivalent period of 2025. Deal share rose from 7% to 10%, while disclosed capital share fell from 13% to 5%. The same period of 2024 showed 9 deals and $122M, making the current transaction count familiar rather than unprecedented.

Hippocratic AI illustrates why a single company's funding can change the impression of the entire category. Its $141M Series B in January 2025 and $126M Series C in November 2025 supported patient-facing AI agents at considerable scale. By contrast, more recent financings such as Confido Health's $12M Series A in October 2026 and Parakeet Health's $10M Series A in October 2026 are smaller. The smaller checks tell us little about product quality. They do show why funding can fall when deal count rises.

Can European healthcare AI agent startups catch up with the US?

European healthcare AI agent startups are raising more money, but North America is still far ahead.

European companies recorded 14 deals and $210M this year to date, versus 12 deals and $164M over the same dates of 2025. Their deal share rose from 12% to 16%. North America still dominated with 67 deals and at least $1.8B this year, representing 83% of disclosed capital. European startups are making progress, but the US funding gap remains wide.

European startups are also addressing different hospital tasks. Tandem Health's $100M Series B in September 2026 supported its path toward a clinic operating system, while Vocca's $20M Series A in October 2026 backed voice agents for providers in France. These companies offer products that can fit different healthcare systems and languages. Europe has a credible funding pipeline, but its distance from the American market remains considerable in both completed rounds and money raised.

Is the US losing its grip on healthcare AI agent funding?

US healthcare AI agent startups still raise most of the money, though their share of deals is shrinking.

U.S.-headquartered companies accounted for 57 deals and 90% of all deals by the equivalent point of 2024. That became 80 deals and 78% over the same window of 2025, then 66 deals and 75% this year. Their share of disclosed capital also moved from 96% to 90% to 83% across those periods. Those are substantial differences in geographic mix, not evidence that American companies stopped being central.

Australia's Heidi Health and Sweden's Tandem Health demonstrate that meaningful funding is now available outside the United States. Brazil also appeared in several healthcare workflow financings this year, including Telepatia AI's $33M Series A in June 2026. These figures count company headquarters, not where customers or investors live. A broader map of funded startups is a real change, while a global balance of capital remains distant.

Are fewer VCs leading healthcare AI agent rounds this year?

Fewer VCs are leading healthcare AI agent rounds than at the same point in 2025.

We identified 72 distinct disclosed lead investors this year to date, versus 105 over the equivalent period of 2025. The overall set of disclosed investors declined from 152 to 108. Lead disclosure coverage was the same, at 88% this year and in the preceding comparison period, making the contraction hard to dismiss as only a reporting difference.

Andreessen Horowitz led 4 tracked rounds this year to date, while Oak HC/FT and Flare Capital Partners each led 3. These are counts of completed deals led, not the sizes of the firms' own checks. Fewer firms are showing up in completed rounds, though some may simply be sitting out this period. With fewer deals overall, some drop in active names is normal, but a drop this big still matters for founders raising money now.

Is it harder for new healthcare AI agent founders to raise?

New healthcare AI agent founders can still raise money, but first financings have become rarer.

Our classification identifies 18 first-financing deals worth $99M this year to date, compared with 31 deals and $213M over the same 2025 period and 17 deals and $113M at the equivalent point of 2024. The share of first financings fell from 30% in the 2025 comparison to 20% today. We count a first financing only when the source says so, so about a fifth of deals in each period stay unclassified. The comparison with 2024 is more nuanced: there were a similar number of first financings then, but the total market was smaller.

Some new products still attract initial backing. Ferry Health's $9M Seed in September 2026 focuses on navigation, and Vali Health's $6M Seed in June 2026 focuses on clinical coordination. Yet competition now includes established startups extending their platforms and record vendors shipping agent-building capabilities. Fewer first rounds closed than in 2025. That says nothing about how many promising founders are still trying.

Are healthcare AI agents actually shipping useful products?

Healthcare AI agent companies are building software for specific hospital tasks, although funding alone cannot prove those tools work at scale.

Suki's October 2026 announcement described expansion beyond ambient notes into clinical reasoning and revenue-cycle workflows. Assort Health's July 2026 update described a platform linking scheduling, referrals, refills and payments. Charta Health's November 2026 release explained how pre-claim chart review supports both providers and payers. Hospitals can test these products against real staff work. Charta Health said in its November 2026 announcement that revenue grew 10x over the preceding 12 months. The figure is a company claim, not audited market-wide growth.

Epic also gives hospitals a way to build their own agents. It showed health systems building agents inside an established electronic health-record platform. For independent startups, the real test is whether work gets done securely, correctly and with proper oversight inside a provider's software, whatever the demo sounds like. Company announcements show genuine products. Their revenue and clinical outcomes still need independent scrutiny.

So, what are the funding trends in healthcare AI agents right now?

Healthcare AI agent funding has cooled from its peak, while normal-sized checks are holding up and seed deals are getting harder to find.

Forus led the year-to-date period by recorded capital raised, with $275M across its May 2026 Series B and September 2026 Series C. The market's overall capital is down relative to the same months of 2025 but still well above comparable 2024 activity. Series A and Series B are taking more of the deal mix, while documentation has lost capital share to billing, operations and other practical workflows.

A growing product category does not guarantee bigger venture totals every year. Health systems increasingly expect automation to complete work, and platforms such as Epic are building agents internally as startups compete for their budgets. Money is still available, but the easiest funding boom is over.

The table below shows what we found.

Question	Answer
Is this year's capital still beating last year's pace?	Healthcare-agent funding has cooled since the peak of the previous period. Disclosed capital fell 21% against the same calendar months of 2025. Fewer giant rounds explain much of that year-on-year drop.
Has the healthcare-agent market fallen back to 2024?	Healthcare AI agent funding remains well ahead of its earlier baseline. Deal count is up 40% against the equivalent 2024 period. The sector has grown even though this year’s funding is cooler.
Has the sector already beaten the full record?	The sector has not yet broken its completed full-year funding record. Current disclosed capital equals 72% of the full 2025 total. This year is still incomplete, so a fair comparison requires care.
Are giant rounds masking stronger ordinary demand?	Smaller healthcare-agent funding rounds have held up better than megarounds. Capital excluding rounds above $50M increased 7% in matched periods. The top end explains much of the apparent market slowdown.
Is the typical funding check becoming smaller?	The typical healthcare-agent round is getting bigger rather than smaller. Its median reached $16M during the current year-to-date period. Fewer seed rounds may be one reason the median has risen.
Did the most recent full-year surge matter?	The previous healthcare-agent funding surge was unusually large and difficult to repeat. Full-year 2025 funding rose 117% compared with full-year 2024. That leaves today’s pullback looking less like a sector collapse.
Is this year's seed pipeline getting broader?	Healthcare-agent seed funding has weakened considerably during the current year. Only 26 seed rounds closed during the year-to-date period. Larger Series A deals have become more prominent instead.
Is Series A taking a larger share now?	Series A now takes a greater share of healthcare-agent funding rounds. It accounted for 43% of deals in the current period. Seed has lost much of its earlier dominance of deal activity.
Are documentation tools still setting the pace?	Medical documentation tools no longer dominate healthcare-agent fundraising like before. That category took 16% of disclosed capital this year. Investors are also backing billing, scheduling and hospital operations.
Have international companies become irrelevant to funding?	The US still dominates healthcare-agent deals, but its share has fallen. American companies accounted for 75% of this year’s completed rounds. Startups in other countries are gaining more ground than before.
Does a good quarter prove a new boom?	One strong capital quarter does not prove a new sector boom. Healthcare AI agents raised $775M during Q3 2026 alone. Deal counts did not rebound in step with that larger total.